ATHE
ALTERITY THERAPEUTICS LTD
$3.90
0.00%
$59.9M
No data for this timeframe.
Vol
Market Cap$59.9M
Cap SizeMicro Cap
Inst. Holders1 funds
Inst. Value$196.1K
Inst. Activity1 buys / 1 sells
SEC Reports2
Press Releases4
Recent Activity
Apr 30, 2026
SEC
Alterity Therapeutics reported Q3 FY26 progress, highlighting FDA alignment on key Phase 3 program elements for ATH434 i
PRESS-RELEASE — Impact 4/10
Mar 26, 2026
SEC
Analysis based on filing metadata only — document content was unavailable
6-K — Impact 2/10
Inst.
MORGAN STANLEY — ADD
58,301 shares ($238.4K)
Inst.
UBS Group AG — EXIT
0 shares ($0.00)
May 19, 2026
other
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
<p align="center"><em>– Alterity’s novel imaging and biomarker approach positions the Company at the
May 11, 2026
Press
Alterity Therapeutics announced a peer-reviewed publication in NeuroImage demonstrating that QSM MRI can detect disease-
Impact 7/10
Apr 27, 2026
Press
Alterity Therapeutics received positive FDA feedback on the chemistry, manufacturing, and control (CMC) aspects of its A
Impact 7/10
Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$12.00 (Dec 2025)
Current $3.90
Low $12.00
Median $12.00
High $12.00
1 analysts
$12.00
$12.00
Analyst Ratings
1Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Dec 17, 2025 | Canaccord Genuity | INITIATE | Speculative Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $-0.87 ▼ -109.3% | $-0.87 — $-0.87 | -67% YoY | 1 |
| Next FY | $-1.18 ▼ -198.4% | $-1.18 — $-1.18 | -36% YoY | 1 |
Latest Reports
BULLISH
Press
7/10
Alterity Therapeutics announced a peer-reviewed publication in NeuroImage demonstrating that QSM MRI can detect disease-
May 11, 2026
NEUTRAL
PRESS-RELEASE
4/10
Alterity Therapeutics reported Q3 FY26 progress, highlighting FDA alignment on key Phase 3 program elements for ATH434 i
Apr 30, 2026
NEUTRAL
6-K
2/10
Analysis based on filing metadata only — document content was unavailable
Mar 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $196.1K | ADD |
1 institutional holders with $196.1K total value (63,682 shares) as of 2025-Q4. Top holders: MORGAN.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 63,682 | $196.1K | 100.0% | ADD +33.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 43,701 | 58,301 | +33.4% | $238.4K | 2025-Q2 |
| UBS Group AG | EXIT | 13,004 | 0 | -100.0% | $0.00 | 2025-Q2 |
| UBS Group AG | DOUBLED | 384 | 13,004 | +3286.5% | $44.9K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 12,685 | 384 | -97.0% | $1.3K | 2024-Q4 |
| CITADEL ADVISORS LLC | EXIT | 11,488 | 0 | -100.0% | $0.00 | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 3.0/10.
BULLISH
7/10
Alterity Therapeutics announced a peer-reviewed publication in NeuroImage demonstrating that QSM MRI
May 11, 2026
BULLISH
7/10
Alterity Therapeutics received positive FDA feedback on the chemistry, manufacturing, and control (C
Apr 27, 2026
BULLISH
8/10
Alterity Therapeutics announced new Phase 2 data for its drug ATH434 in Multiple System Atrophy (MSA
Apr 22, 2026
BULLISH
8/10
Alterity Therapeutics highlighted positive Phase 2 clinical data for its lead candidate ATH434 in Mu
Mar 2, 2026
Historical analyst distribution (last covering-analyst action Dec 2025): 80% buy across 5 analysts — 1 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$12.00 mean target (Dec 2025)
$12.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $3.90 |
| Target Low | $12.00 |
| Target Mean | $12.00 |
| Target Median | $12.00 |
| Target High | $12.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-06-30 |
$-0.87 | $-0.87 | $-0.87 | -67.0% | -109.3% | 1↑ 0↓ | $0.0B | -34.8% | 1 |
| Next FY 2027-06-30 |
$-1.18 | $-1.18 | $-1.18 | -35.6% | -198.4% | 1↑ 0↓ | $0.0B | -67.5% | 1 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Dec 17, 2025 | Canaccord Genuity | INITIATE | — | Speculative Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| May 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Apr 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Mar 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Feb 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Jan 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 19, 2026
other
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
<p align="center"><em>– Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – </em></p>
May 11, 2026
fda
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
<p align="center"><em>– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulatio
May 7, 2026
other
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
<p align="justify">MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=9Qfl
Apr 30, 2026
earnings
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
<p align="justify"><strong>Highlights</strong></p>
Apr 27, 2026
fda
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
<p align="justify">MELBOURNE, Australia and SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Gh
Apr 22, 2026
fda
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
<p align="center">- <em>ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale -</em></p>
Apr 17, 2026
other
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
<p align="justify">MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=gu
Apr 16, 2026
routine
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
<p align="justify">MELBOURNE, Australia and SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2u
Apr 15, 2026
other
Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
<p align="justify">MELBOURNE, Australia and SAN FRANCISCO, April 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=mC
Mar 30, 2026
fda
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
Alignment reached on key elements of ATH434 Phase 3 development program <pre>Alignment reached on key elements of ATH434 Phase 3 development program</
Mar 9, 2026
other
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
<p align="justify">MELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=fp
Mar 4, 2026
other
Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
– Neurology and Movement Disorder Specialist Adds Deep Clinical and Development Expertise – <pre>– Neurology and Movement Disorder Specialist Adds Dee
Mar 2, 2026
fda
Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
<p align="center"><em>– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegener